Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scholar Rock HoldingFRA:2QK +0.61%34 Debt-to-Equity is 0.80 as of Jun. 2026, which is 220% above its 10-year median of 0.25. GuruFocus rates FRA:2QK with a GF Score™ of 34/100 and a GF Value™ of €25.26 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 956 Biotechnology companies, Scholar Rock Holding ranks worse than 83.68% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Scholar Rock Holding's Debt-to-Equity or its related term are showing as below:
FRA:2QK'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.06 Med: 0.25 Max: 0.84
Current: 0.8
During the past 10 years, the highest Debt-to-Equity Ratio of Scholar Rock Holding was 0.84. The lowest was -0.06. And the median was 0.25.
FRA:2QK's Debt-to-Equity is ranked worse than 83.68% of 956
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:2QK: 0.80
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Scholar Rock Holding Debt-to-Equity Related Terms
Scholar Rock Holding Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Scholar Rock Holding's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2QK vs DFTX, DNTH, ORKA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Scholar Rock Holding's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scholar Rock Holding Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scholar Rock Holding's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Scholar Rock Holding's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scholar Rock Holding (FRA:2QK) has a Debt-to-Equity of 0.80 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Scholar Rock Holding and its competitors. This is 220% above median its historical median of 0.25. According to the industry distribution chart, Scholar Rock Holding ranks #800 out of 956 companies in the Biotechnology industry, placing it in the top 83.7%.
Is Scholar Rock Holding's Debt-to-Equity too high?
Scholar Rock Holding's current Debt-to-Equity of 0.80 is 220% above median its 10-year median of 0.25. The Biotechnology industry median Debt-to-Equity is 0.16. Scholar Rock Holding's value of 0.80 is 400% above this industry median. Based on the distribution chart, Scholar Rock Holding ranks #800 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scholar Rock Holding has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's Debt-to-Equity compare to DFTX and DNTH?
According to the Biotechnology industry distribution chart, Scholar Rock Holding ranks #800 out of 956 companies for Debt-to-Equity. This places Scholar Rock Holding in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Scholar Rock Holding's value of 0.80 is 400% above this benchmark. While the company's 10-year median is 0.25 vs. the industry median of 0.16, Scholar Rock Holding has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scholar Rock Holding's current Debt-to-Equity of 0.80 is 400% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Scholar Rock Holding and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scholar Rock Holding's current Debt-to-Equity is 0.80, which is 220% above median its own 10-year median of 0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Based on GuruFocus' analysis, Scholar Rock Holding (FRA:2QK) is currently considered Significantly Overvalued. The stock's GF Value™ is €25.26, compared to a current price of €49.24 — trading 94.9% above its estimated fair value. The current Debt-to-Equity is 0.80, which is 220% above median its 10-year median of 0.25 and 400% above the Biotechnology industry median of 0.16. Scholar Rock Holding's overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current Debt-to-Equity is 0.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scholar Rock Holding (FRA:2QK) Overvalued in 2026?
Based on GuruFocus' analysis, Scholar Rock Holding stock appears to be overvalued.
The current stock price of €49.24 is trading 94.9% above its estimated GF Value™ of €25.26.
GuruFocus considers Scholar Rock Holding to be Significantly Overvalued.
Key valuation signals for FRA:2QK:
Debt-to-Equity: 0.80 (220% above median its 10-year median of 0.25)
GF Value™: €25.26 vs. price of €49.24 (94.9% above fair value)
Industry Position: 400% above the Biotechnology median (#800 of 956)
No single metric tells the full story. See the FRA:2QK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
34GF Score
Get the complete analysis for FRA:2QK
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2QK has been successfully added to your 
